Chemomab Therapeutics (CMMB) Operating Income (2017 - 2019)
Chemomab Therapeutics posted quarterly Operating Income of $3.9 million for Q3 2019, up 55.57% year-on-year from $2.5 million in Q3 2018, and down 12.29% on a QoQ basis from $4.4 million in Q2 2019.
Chemomab Therapeutics (CMMB) has 3 years of Operating Income data on file, last reported at $3.9 million in Q3 2019.
- For the quarter ending Q3 2019, Operating Income rose 55.57% year-over-year to $3.9 million; the trailing twelve-month figure through Sep 2019 stood at $16.8 million (up 40.17% YoY), and the FY2018 full-year result was -$13.0 million, down 38.88% from the prior year.
- Operating Income for Q3 2019 stood at $3.9 million, down from $4.4 million in the prior quarter.
- Across five years, Operating Income topped out at $5.4 million in Q1 2019 and bottomed at $1.9 million in Q4 2017.
- The 3-year median for Operating Income is $3.6 million (2018), against an average of $3.6 million.
- Peak annual rise in Operating Income reached 59.78% in 2019, while the deepest fall reached 6.75% in 2019.
- A 3-year view of Operating Income shows it stood at $1.9 million in 2017, then jumped by 58.13% to $3.0 million in 2018, then soared by 30.95% to $3.9 million in 2019.
- The last three Operating Income figures came in at $3.9 million (Q3 2019), $4.4 million (Q2 2019), and $5.4 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 3.90 Mn |
| Jun 30, 2019 | 4.44 Mn |
| Mar 31, 2019 | 5.43 Mn |
| Dec 31, 2018 | 2.98 Mn |
| Sep 30, 2018 | 2.51 Mn |
| Jun 30, 2018 | 4.16 Mn |
| Mar 31, 2018 | 3.40 Mn |
| Dec 31, 2017 | 1.88 Mn |